Monte Rosa Therapeutics (GLUE) Current Deferred Revenue (2023 - 2026)

Monte Rosa Therapeutics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $103.6 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 514.57% year-over-year to $103.6 million; the TTM figure through Mar 2026 stood at $103.6 million (up 514.57% YoY), while the FY2025 annual figure was $111.3 million, down 5.03% from the prior year.
• Current Deferred Revenue was $103.6 million for Q1 2026 at Monte Rosa Therapeutics, down from $111.3 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $117.2 million in Q4 2024 to a low of $16.9 million in Q1 2025.
• Historically, Current Deferred Revenue has averaged $51.2 million across 4 years, with a median of $30.4 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Current Deferred Revenue tumbled 45.2% in 2025, then jumped 514.57% in 2026.
• A 4-year view of Current Deferred Revenue shows it stood at $32.3 million in 2023, then surged by 262.69% to $117.2 million in 2024, then dropped by 5.03% to $111.3 million in 2025, then declined by 6.91% to $103.6 million in 2026.
• The last three Current Deferred Revenue figures came in at $103.6 million (Q1 2026), $111.3 million (Q4 2025), and $24.8 million (Q3 2025), per Business Quant data.